Abstract:Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced stage, with systemic therapy being the mainstay of treatment. Survival continues to be limited, typically less than 1 year. The PDAC microenvironment is characterized by a paucity of malignant epithelial cells, abundant stroma with predominantly immunosuppressive T cells and myelosuppressive-type macrophages (M2), and hypovascularity. The current treatment options for metastatic PDAC are modified (m)FOLFIRINOX /FOLFIRINOX or nab-paclitaxel and gemcitabine in patients with good performance status (PS) (ECOG 0-1/KPS 70-100%) and gemcitabine with or without a second agent for those with ECOG PS 2-3. New therapies are emerging, and the current guidelines endorse both germline and somatic testing in PDAC to evaluate actionable findings. Important themes related to new therapeutic approaches include DNA damage repair strategies, immunotherapy, targeting the stroma, and cancer-cell metabolism. Targeted therapy alone (outside small genomically defined subsets) or in combination with standard cytotoxic therapy, thus far, has proven disappointing in PDAC; however, novel therapies are evolving with increased integration of genomic profiling along with a better understanding of the tumor microenvironment and immunology. A small but important sub-group of patients have some of these agents available in the clinics for use. Olaparib was recently approved by the US Food and Drug Administration for maintenance therapy in germline BRCA1/2 mutated PDAC following demonstration of survival benefit in a phase 3 trial. Pembrolizumab is approved for patients with defects in mismatch repair/microsatellite instability. PDAC with wild-type KRAS represents a unique subgroup who have enrichment of potentially targetable oncogenic drivers. Small-molecule inhibitors including ERBB inhibitors (e.g., afatinib, MCLA-128), TRK inhibitors (e.g., larotrectinib, entrectinib), ALK/ROS inhibitor (e.g., crizotinib), and BRAF/MEK inhibitors are in development. In a small subset of patients with the KRASG12C mutation, a KRASG12C inhibitor, AMG510, and other agents are being investigated. Major efforts are underway to effectively target the tumor microenvironment and to integrate immunotherapy into the treatment of PDAC, and although thus far the impact has been modest to ineffective, nonetheless, there is optimism that some of the challenges will be overcome.

Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review

Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities

Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine

Targeted Therapeutic Approaches for the Deadliest Cancer

Biological Characteristics of Pancreatic Ductal Adenocarcinoma: Initiation to Malignancy, Intracellular to Extracellular.

Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling

Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments

Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy

Recent advances in drug delivery and targeting for the treatment of pancreatic cancer

The role of molecular testing in pancreatic cancer

New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology

Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy—A Review of the Literature

Target and Gene-Based Therapeutic Strategies against Pancreatic Cancer: Current and Future Prospects

Challenges in developing targeted therapy for pancreatic adenocarcinoma

Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications

[Molecular Targeted Therapy Strategy and Clinical Research Progress in Pancreatic Ductal Adenocarcinoma].

Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer

Therapeutic developments in pancreatic cancer